SNY - Dianthus: Improved Autoimmune Disorder Targeting With Classical Pathway Inhibition

2024-07-29 15:45:45 ET

Summary

• Dianthus Therapeutics, Inc.'s DNTH103 is being evaluated in the phase 2 MaGic trial, which is targeting patients with generalized myasthenia gravis.
• The global myasthenia gravis treatment market size is estimated to reach $2.2 billion by 2028; Up to 85% of MG patients are said to have the generalized form of the disease.
• Two other indications being explored in the pipeline with the advancement of DNTH103 are multifocal motor neuropathy and chronic inflammatory demyelinating polyneuropathy.
• The company had $377 million in cash as of March 31st, 2024; Enough cash to fund its operations into the 2nd half of 2027.

Dianthus Therapeutics, Inc. ( DNTH ) is advancing its potential best-in-class complement inhibitor drug DNTH103 for a wide variety of autoimmune disorders. In particular, it is looking at advancing the targeting of the classical C1s component observed in these disorders. However, doing so with the advantage of selectivity, which could ultimately yield several competitive advantages compared to other complement inhibitors approved or in clinical development. The lead program from the company is the evaluation of DNTH103 for the treatment of patients with Generalized Myasthenia Gravis [gMG] in the ongoing phase 2 MaGic trial....

For further details see: